Novartis is acing the game by providing job opportunities and healthcare to the world

Novartis, one of the largest pharmaceutical companies, is expanding its reach worldwide to provide healthcare and jobs to the people. After Novo Nordisk and Roche, Novartis is Europe's third-largest pharma company. With more than 76,000 employees around the globe in the year 2023, Novartis is supporting more people by offering jobs in Singapore. 

While working in the therapeutic areas, namely Cardiovascular, Renal, metabolic diseases, Neuroscience, Oncology and Immunology, Novartis is now focusing on growing its Antibody manufacturing project. As per the press release by Novartis, the prominent pharma player is ready to augment its market in Singapore by expanding its antibody manufacturing project; through this action, the leading biopharmaceutical company aims to meet the rising demand in the Asian market. 

On March 15th, the Swiss pharmaceutical giant announced its commencement of a $256 million expansion initiative at its biopharmaceutical production facility in Singapore. This endeavor will incorporate digitalization and automation technologies to enhance its manufacturing efficiency. Besides this, it will also facilitate skill development within the company's workforce.

The expanded facility will specialize in manufacturing therapeutic antibody drugs to provide groundbreaking medical treatments to patients around the globe.

Mr. Heng Swee Keat, Deputy Prime Minister and Coordinating Minister for Economic Policies, emphasized the necessity of advancements in the manufacturing industry to ensure sustainability and productivity in the biopharmaceutical sector. He underscored continual innovation's significance in developing targeted, precise, and efficacious drugs. Leveraging Singapore's substantial biomedical investments and the well-established ecosystem, global collaborations such as with Novartis are poised to deliver cutting-edge biologics to combat diseases and enhance health outcomes regionally and internationally.